AbCellera Biologics Inc. (ABCL) Total liabilities 2020–2025
AbCellera Biologics Inc. (ABCL) total liabilities at each fiscal year-end, per SEC filings.
$390.0MFY2025 · since FY2020: $175.0M → $390.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $390.0M | +28.1% |
| FY2024 | $304.5M | -9.3% |
| FY2023 | $335.8M | +9.1% |
| FY2022 | $307.6M | +5.1% |
| FY2021 | $292.8M | +67.3% |
| FY2020 | $175.0M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ABCL financial trends
ABCL RevenueABCL Net incomeABCL Net marginABCL Gross profitABCL Gross marginABCL Operating incomeABCL Operating marginABCL Operating cash flowABCL Free cash flowABCL Capital expendituresABCL Return on equityABCL Stock buybacksABCL Dividends paidABCL Total assetsABCL Shareholders’ equityABCL overview →